Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.45 and traded as high as $1.8550. Lexicon Pharmaceuticals shares last traded at $1.68, with a volume of 2,204,482 shares traded.
Analyst Upgrades and Downgrades
Several analysts have issued reports on LXRX shares. HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, March 23rd. Citigroup lifted their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the stock a "buy" rating in a report on Tuesday, March 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has an average rating of "Hold" and an average target price of $4.15.
Check Out Our Latest Analysis on LXRX
Lexicon Pharmaceuticals Price Performance
The business's 50-day moving average price is $1.62 and its 200 day moving average price is $1.45. The company has a quick ratio of 4.87, a current ratio of 4.88 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $711.78 million, a P/E ratio of -12.00 and a beta of 0.94.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 101.08% and a negative return on equity of 41.94%. Analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.19 EPS for the current fiscal year.
Insiders Place Their Bets
In other Lexicon Pharmaceuticals news, Director Raymond Debbane purchased 100,000 shares of the company's stock in a transaction dated Monday, February 23rd. The stock was purchased at an average price of $1.47 per share, for a total transaction of $147,000.00. Following the transaction, the director owned 1,904,186 shares in the company, valued at $2,799,153.42. The trade was a 5.54% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Invus Global Management, Llc acquired 1,538,462 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the acquisition, the director directly owned 1,538,462 shares of the company's stock, valued at $2,000,000.60. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 1,790,462 shares of company stock worth $2,369,981 in the last quarter. 14.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Lexicon Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE lifted its position in Lexicon Pharmaceuticals by 27.4% during the fourth quarter. Bank of America Corp DE now owns 136,407 shares of the biopharmaceutical company's stock valued at $101,000 after purchasing an additional 29,319 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Lexicon Pharmaceuticals by 173.5% in the 1st quarter. Invesco Ltd. now owns 285,759 shares of the biopharmaceutical company's stock worth $132,000 after buying an additional 181,265 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at $541,000. Acadian Asset Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth $263,000. Finally, XTX Topco Ltd lifted its holdings in shares of Lexicon Pharmaceuticals by 431.4% during the 2nd quarter. XTX Topco Ltd now owns 66,276 shares of the biopharmaceutical company's stock worth $63,000 after acquiring an additional 53,805 shares during the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.
Lexicon Pharmaceuticals Company Profile
(
Get Free Report)
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon's approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company's most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
